Rovalpituzumab tesirine

Drug Profile

Rovalpituzumab tesirine

Alternative Names: Rova-T; SC16LD6.5

Latest Information Update: 14 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stemcentrx
  • Developer Bristol-Myers Squibb; Stemcentrx
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DLL3 protein inhibitors; DNA modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 07 Nov 2017 AbbVie plans a phase IIIb trial in Small cell lung cancer (Second-line therapy or greater) (NCT03334487)
  • 08 Sep 2017 Interim adverse events data from a phase I/II trial in Solid tumours presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 02 Jun 2017 Pharmacodynamics data from a phase I/II trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top